Access Insights: How Immunomedics Leveraged IntegriChain’s Refined Channel and CRM Data for a Successful Specialty Launch

October 21, 2020 | 10:00 am ET

Siloed channel and market access data — combined with disconnected master data across the commercial systems landscape — creates a number of obstacles to a successful product launch and proactive engagement for both buy-and-bill and “specialty light” products. In this session, we’ll examine how Immunomedics implemented commercial analytics to support TrodelvyTM including territory performance  reporting, incentive compensation, and enhanced targeting. We’ll also examine how to utilize unblinded 867 data as a foundational asset, and integrate it with the Veeva commercial data warehouse and CRM solution to improve visibility and value.

Please join Joshua Halpern, Co-Founder and EVP, Product and Strategy and Ushank Agarwal, Senior Director, Commercial Analytics, Immunomedics.

josh halpern

    Watch now!

    adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand